

Organic & Biomolecular Chemistry

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: N. Esmati, A. R. Maddirala, N. A. Hussein, H. A. Amawi, A. Tiwari and P. R. Andreana, *Org. Biomol. Chem.*, 2018, DOI: 10.1039/C8OB00452H.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [author guidelines](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the ethical guidelines, outlined in our [author and reviewer resource centre](#), still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



Journal Name

ARTICLE

Efficient Syntheses and Anti-Cancer Activity of Xenortides A-D Including *ent/epi*-Stereoisomers

N. Esmati^a, A. R. Maddirala^a, N. Hussein^b, H. Amawi^{b,#}, A. K. Tiwari^b and P. R. Andreana^{*a}

A one-pot, two-step, total synthesis of naturally occurring Xenortides A, B, C and D, (Xens A-D) isolated from the bacterium *Xenorhabdus nematophila*, and an entire complementary set of stereoisomers, has been achieved. Compounds were synthesized utilizing an isocyanide-based Ugi 4-CR followed by facile *N*-Boc deprotection. The reaction sequence took advantage of the chiral pool of *N*-Boc protected amino acids (L-Leu/Val and D-Leu/Val) with aryl isocyanides, phenyl acetaldehyde and methylamine giving the desired Xens A-D (A and B >98% *ee*) and all subsequent stereoisomers in reasonable yields upon deprotection followed by separation of diastereomers. Also, detailed mechanistic insights for diastereoselectivity of (-)-Xen A, as a model in the Ugi 4-CR, has been described. Moreover, for the first time, this focused library was screened for cytotoxicity against a panel of epithelial cancer cell lines as well as normal cell lines with an MTT proliferation assay. The structure–activity relationship (SAR) study demonstrated that tryptamides Xen B and D were more active than phenylethylamides Xen A and C. Furthermore, (-)-Xen B (IC₅₀ = 19–25 μM) and *ent*-(+)-Xen D (IC₅₀ = 21–26 μM) gave the highest cytotoxicity and they were also found to be non-toxic toward normal cells. Importantly, the SAR results indicate that the stereochemistry at C₈ and C₁₁ in (-)-Xen B and *ent*-(+)-Xen D play a critical role in cytotoxic activity.

^a Department of Chemistry and Biochemistry and School of Green Chemistry and Engineering, The University of Toledo, 2801 W. Bancroft St, Toledo, OH 43606

^b Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, OH 43606, US

[#] Current address: Department of Pharmacy Practice, College of Pharmacy, Yarmouk University, Irbid, Jordan 21163

Introduction

Cancer is the second leading cause of death globally and as reported by the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015.¹ Despite an overall positive progression in cancer chemotherapy, limited improvements in patient survival has been documented in many countries and death rates are increasing. Multidrug resistance, lack of selective chemotherapeutic drugs against target tumor cells and severe side effects are major limitations for the availability of anticancer agents.² The treatment of cancer has been a serious concern in public health and urgent development of novel classes of therapeutic agents or anticancer drugs with improved efficacy are in high demand.^{3,4} Peptides, compared to other small organic molecules and proteinaceous immunotherapeutics, have several desirable properties such as high activity, low immunogenicity, good

biocompatibility, and they are readily amenable to synthetic modifications.^{5, 6} As such, peptides have become promising molecules for anticancer agents.⁷⁻⁹ It is therefore important to strategize an efficient synthetic approach that can eliminate any unwanted material during the process to find an optimal molecule consisting of the most appropriate structural conformation.¹⁰

It is well-known that secondary bacteria and fungi metabolites are valuable sources of chemotherapeutic agents.^{11, 12} Bacterial secondary metabolites, Xenortides (Xens) A-D (**Scheme 1**), are a family of natural products extracted from the bacterium *Xenorhabdus nematophilus*.¹³⁻¹⁵ Xen A and C consist of *N*-phenylethylamide derivatives of the dipeptide (*N*-Me-L-Leu and *N*-Me-L-Phe) and (*N*-Me-L-Val and *N*-Me-L-Phe), respectively. The counterparts, (-)-Xen B and D, consist of tryptamide derivatives of the dipeptide (*N*-Me-L-Leu and *N*-Me-L-Phe) and (*N*-Me-L-Val and *N*-Me-L-Phe) respectively. Recent observations by Reimer et al. suggest that these compounds have some anti-parasitic activities.¹⁴ In view of aforementioned biological activities of naturally occurring Xens A-D and our longstanding interest in eradicating cancer,¹⁶⁻¹⁹ exploring the potential anticancer activity of these and derivative compounds, encouraged us to devise a facile synthetic approach for naturally occurring Xen compounds and a cohort of stereoisomers. Here within, we document our synthetic strategy to Xens A-D including all possible stereoisomers. Furthermore, we demonstrate compound bio-potential by examining anticancer activity of each isomer in several epithelial cancer cells. Moreover, this study represents the first anticancer activity report on the Xen family.


Recently, the synthesis of (-)-Xen D was reported by Reimer et al.¹⁴ (-)-Xen D was synthesized via standard peptide coupling reaction conditions using several expensive peptide coupling reagents and multi-step syntheses giving rise to several purification procedures. Furthermore, the aforementioned strategy would not be easily accessible to a small library of derivatives as further synthetic manipulations would be required. These limitations encouraged us to devise a streamlined chemical route toward the synthesis of highly enantiopure Xens. To the best of our knowledge, there are no literature reports describing the synthesis of the complete set of Xen natural products and their *ent/epi*-stereoisomers. Moreover, we believe that the synthesis of highly enantiopure natural Xens A-D and their related stereoisomers may shed light on how the stereochemical properties of chiral, non-racemic Xens play out in anticancer studies, which have never been previously attempted. In the context of developing simple structural manipulations of the starting materials and atom-economical synthetic routes for the synthesis of Xens and all their stereoisomers, we designed an efficient and effective synthetic strategy employing an Ugi four component reaction (4-CR) process.²⁰⁻²³ Our synthetic strategy, involving only two sequential steps, accomplished in a single pot, allows us to obtain the desired compounds in a highly stereoselective fashion using readily available commercial starting materials. As such, this approach is highly efficient, allowing for Xenortide library development with every possible

stereochemical combination, which is standard for SAR studies, following the mantra of medicinal and biological chemistry. Our retrosynthetic analysis for those compounds is shown in **Scheme 1**.


Results and Discussion

Chemistry

Synthetic efforts commenced with synthesizing phenylethyl isocyanide (**1a**²⁴) and indole ethyl isocyanide (**1b**²⁵) as required precursors in the Ugi 4-CR. These compounds were synthesized through common formylation²⁶ and dehydration^{27, 28} procedures. Formylation was achieved via refluxing the aryl ethylamine (**1a'** and **1b'**) with ethyl formate for 6 h. A solution of the related aryl ethyl formate (**1a''** and **1b''**) and Et₃N in anhydrous dichloromethane was treated with POCl₃ at -78 °C for 3 h to furnish the required isocyanides in nearly quantitative yields **Scheme 2**.




Scheme 1. Retrosynthetic approach to naturally occurring Xens A-D using an Ugi 4-CR (**1(a,b)** + **2** + **3** + **4(a,b)**).



Scheme 2. Formylation and dehydration for the synthesis of aryl isocyanides **1a** and **1b**.


Having precursors **1a** and **1b** in hand, we began our two-step synthetic protocol of (-)-Xen A (**5**) and *epi*-(+)-Xen A (**5a**) (**Scheme 3**). The reaction was designed to employ stoichiometric equivalents of phenylethyl isocyanide (**1a**), phenyl acetaldehyde (**2**), methylamine (**3**) (33% weight in ethanol) and Boc-*N*-methyl-L-leucine (**4a**) which readily dissolved in methanol as the solvent. The reaction was then

stirred at room temperature for 24 h. The resultant mixture led to the formation of two diastereomers, which were readily visualized using TLC; R_f values of 0.5 and 0.8. However, due to the formation of rotamers during ^1H NMR analysis, we were unable to quantitate the actual diastereomeric ratios of the unpurified mixture of **5'** and **5a'**. We have performed NMR studies at high temperature in an attempt to clarify the rotameric issue, however, complete coalescence was not achieved. After careful separation of the Boc protected diastereomers using silica gel column chromatography with hexane and ethyl acetate as the eluents, ^1H NMR analysis was conducted for individual diastereomers **5'** and **5a'**. Unfortunately, rotamers were once again problematic and definitive NMR characterization continued to be elusive. Compounds **5'** and **5a'** were then subjected to Boc deprotection using 50% TFA in DCM at 0 °C for 2 h (Scheme 4). After TLC indicated complete Boc deprotection, isolation and purification of the individual (-)-Xen A (**5**) and *epi*-(+)-Xen A (**5a**) ensued using heptane and ethyl acetate as the solvents with normal phase silica gel chromatography. Pure compounds were then subjected to ^1H NMR spectral analysis and at this point we did not observe rotamers, which had plagued our ability to properly characterize other intermediates as previously stated. All of the NMR spectral analysis and the optical rotary values observed for compounds **5** and **5a** gave identical peak matching to previous literature reports.^{13, 14}



Scheme 3. Two-step synthesis of (-)-Xen A (**5**) and *epi*-(+)-Xen A (**5a**).

To by-pass the rotameric issue that we encountered with the initial two-step sequence and our problem quantifying diastereomeric ratios of intermediates using ^1H NMR analysis, we elected to alter our synthetic strategy and re-design our approach that would include a one pot, two-step synthetic process (Scheme 4).



Scheme 4. One-pot, two-step synthesis of **5** and **5a**.

To further support a more efficient and effective process to Xens A-D, the strategy was intended to avoid tedious workup and purifications of Boc-protected compounds such as **5'** and **5a'**.

In formalizing the one-pot, two-step synthetic process for (-)-Xen A (**5**) and *epi*-(+)-Xen A (**5a**) (Scheme 4), we decided to follow the exact route for the synthesis of the other Xen family of natural products. Therefore, in all cases, when TLC and mass spectral analysis indicated completion, methanol was evaporated under reduced pressure and without any further purification, the crude mixture was subjected to the Boc deprotection conditions which consisted of 50% TFA in DCM at 0 °C followed by stirring for 2 h.


The unpurified mixture of (+/-)-Xens A-D was then analyzed using ^1H NMR to determine diastereomeric ratios and then silica gel column chromatography with heptane and ethyl acetate as the solvent system was used to isolate our target molecules. Further NMR spectral analysis of the individually isolated pure compounds was conducted and peak shift values were observed matching exactly to those found in the literature.^{13, 14}

At this point in the study, we elected to conduct a detailed investigation on the effect of temperature on diastereoselectivity. Reactions were subjected to conditions at 0 °C, room temperature and 40 °C all the while maintaining consistency with a 24 h reaction time-frame using methanol as the solvent. From these studies, we observed that room temperature conditions gave the best diastereomeric ratios of 1.5:1 when compounds **1a**, **2**, **3**, **4a** were used (Table 1).

All the other natural Xens and their stereoisomers were obtained employing the conditions noted in entry 2; Table 1. Using the noted conditions enabled us to access a small library

of Xen derivatives with isocyanides **1a** and **1b** along with L-Leu and L-Val. Diastereomeric ratios were again determined using ¹H NMR and R_f values of each diastereomer in heptane/ethyl acetate (4:1) were noted as documented in **Table 2**.

Table 1. Effect of temperature on the one-pot synthesis.



entry	conditions	diastereomeric ratio ^a [5 (<i>S,S</i>):5a (<i>S,R</i>)]	^b yield (%) 5 (<i>S,S</i>)	^b yield (%) 5a (<i>S,R</i>)
1	MeOH, 0 °C, 24 h	1.3:1	15	<5
2	MeOH, r.t., 24 h	1.5:1	27	18
3	MeOH, 40 °C, 24 h	1.1:1	17	13


^aDiastereomeric ratios determined using ¹H NMR analysis of the unpurified reaction mixture ($T_1 = 3.5$). ^bCompounds purified using silica gel chromatography with heptane and ethyl acetate as the solvents.

Table 2. A one-pot, two-step reaction sequence for (+/-) and epi-(+/-)-Xens.

entry	R	R'	^a product	^b diastereomeric ratio	R _f (cm)
1	Ph	(L-Leu) - 4a	(-)-Xen A (5)/epi-(+)-Xen A (5a)	1.5:1.0	0.5/0.8
2	3-Indole	(L-Leu) - 4a	(-)-Xen B (6)/epi-(+)-Xen B (6a)	1.5:1.0	0.3/0.6
3	Ph	(L-Val) - 4b	(-)-Xen C (7)/epi-(+)-Xen C (7a)	1.3:1.0	0.5/0.7
4	3-Indole	(L-Val) - 4b	(-)-Xen D (8)/epi-(+)-Xen D (8a)	1.3:1.0	0.4/0.7
5	Ph	(D-Leu) - 4c	ent-(+)-Xen A (5b)/ent-epi(-)-Xen A (5c)	1.0:1.3	0.3/0.6
6	3-Indole	(D-Leu) - 4c	ent-(+)-Xen B (6b)/ent-epi(-)-Xen B (6c)	1.0:1.4	0.5/0.8
7	Ph	(D-Val) - 4d	ent-(+)-Xen C (7b)/ent-epi(-)-Xen C (7c)	1.0:1.1	0.5/0.8
8	3-Indole	(D-Val) - 4d	ent-(+)-Xen D (8b)/ent-epi(-)-Xen D (8c)	1.0:1.5	0.4/0.6

^aCompounds purified using silica gel chromatography with heptane and ethyl acetate as the solvents. ^bDiastereomeric ratios determined using ¹H NMR analysis of the crude reaction mixture.

In all cases, formation of diastereomers with (*S*) configuration at C₈ were favored over those with the (*R*) configuration (**Scheme 5**).²⁹⁻³² We assume that preferable formation of the *S*-diastereomer in all synthesized compounds can be explained in the detailed mechanism of (-)-Xen A (**5**) as a model in the Ugi 4-CR. In this mechanism, we propose that nucleophilic attack by the phenylethyl isocyanide (**1a**) occurs from the *Re*-face of the thermodynamically more stable (*E*)-imine, which forms first in the equilibrium sequence of events between **2** and **3** (**I**). We argue that this is made possible through hydrogen-bond donation of amino acids **4a-4d**, which block the *Si*-face of the (*E*)-imine and leads to the slightly preferred (*S*) configuration at C₈ (**II**). What follows next is attack on the nitrilium ion by the carboxylate leading to intermediate (**III**) which undergoes the Mumm rearrangement³⁰ which in the rate determining step giving **5'**, which, when treated with TFA in DCM renders (-)-Xen A (**5**) as the major diastereomer after purification.



Scheme 5. Plausible mechanism for diastereoselectivity in the Ugi 4-CR.

Under the conditions noted, all desired target products were obtained in fair to moderate yields. We were able to calculate the enantioselectivities for (-)-Xen A/B and *ent*-(+)-Xen A/B using specific optical rotation values of those compounds reported in literature² (Table 3). The excellent optical rotary values observed between our compounds and those published reveal that retention of chirality is maintained in the *N*-Boc protected amino acids (L/D-Leu) under our protocol. This further validates that under our noted reaction conditions no racemization at C₁₁ occurred.

Biological Studies

After completing the synthesis of Xen compounds noted in Table 3, we turned our attention to cytotoxicity analyses using five different cancer cell lines; colon carcinoma (HCT-116), human lung carcinoma (H460), human ovarian carcinoma (OV-2008), human breast adenocarcinoma (MDA-MB-231), and human prostate adenocarcinoma (DU-145), as well as normal cell lines human epithelial colon (CRL-1459) and Chinese hamster ovarian cells (CHO) using the MTT assay.^{33, 34} The antiproliferative efficacy data are presented as IC₅₀ values defined as the concentration of the compound that decreases cell proliferation at 50% (Table 4). The IC₅₀ values were generated from at least three independent experiments. Cell survival was determined by MTT assay as described in materials and methods.

Cytotoxicity Evaluation and the Structure Activity Relationships Study

The influence of chirality at C₈ and C₁₁ on cytotoxicity of naturally occurring Xens A-D and all their stereoisomers (enantiomers and diastereomers) were investigated and some interesting results were observed from this focused library of compounds. Tryptamides Xen B and D stereoisomers were overall more active than the phenylethylamides Xen A and C stereoisomers. It was also previously reported that tryptamides (-)-Xen B and D, natural products were more active than natural phenylethylamides (-)-Xen A and C against sleeping sickness (*Trypanosoma brucei rhodesiense*) and malaria (*Plasmodium falciparum*) diseases.¹⁴ These data together suggest that tryptamide analogues play a significant role in the enhancement of biological activity of the Xen family.

In addition, (-)-Xen B and *ent*-(+)-Xen D were found to be most active among all tested compounds. (-)-Xen B at 19-25 μM produced significant morphological changes against a total of five tested cancer cell lines, HCT-116, H460, OV-2008, MDA-MB-23, DU-145 (Figure 1). Also, *ent*-(+)-Xen D had a 21-26 μM cytotoxicity, selective against three tested cancer cell lines that included HCT-116, OV-2008 and MDA-MB-23. Moreover, inspecting the cytotoxicity of active compounds ((-)-Xen B and *ent*-(+)-Xen D), in comparison to their related stereoisomers, revealed that although they have the same chemical structures, they exhibit distinct differences in anticancer activities. For example, natural (-)-Xen B in comparison to its enantiomer, *ent*-(+)-Xen B, revealed markedly more cytotoxic activity (IC₅₀ = 19-25 μM) than its enantiomer (IC₅₀ = 41-100 μM) in all evaluated cancer lines. Similarly, *ent*-(+)-Xen D exhibited significantly higher cytotoxic activity than its enantiomer (-)-Xen D, with IC₅₀ values of 21-50 μM and > 100 μM, respectively. Furthermore, in this study, the potency of the most active compounds was considerably greater for cancer cells when compared to the normal cells, meaning that no toxicity was recorded toward normal cell lines CRL-1459 and CHO. (These compounds were noted to be considerably safe when tested on the normal cell lines.) (Figure 2). Cisplatin, a well-known anticancer agent, was used as a positive control in our experiments. We observed that although, cisplatin killed the cancer cells at a concentration range of 8-14 μM, they were less selective compared to Xen on normal cells (Table 4).

Table	3.	Library	of	natural	and	unnatural	Xens.
		compound	name	^a yield (%)		^b % ee	
		5	(-)-Xen A	27		>98	
		5a	<i>epi</i> -(+)-Xen A	18		-	
		5b	<i>ent</i> -(+)-Xen A	15		>98	

5c	<i>ent-epi(-)-Xen A</i>	19	–
6	(-)-Xen B	28	>98
6a	<i>epi(+)-Xen B</i>	19	–
6b	<i>ent(+)-Xen B</i>	20	>98
6c	<i>ent-epi(-)-Xen B</i>	28	–
7	(-)-Xen C	25	–
7a	<i>epi(+)-Xen C</i>	19	–
7b	<i>ent(+)-Xen C</i>	21	–
7c	<i>ent-epi(-)-Xen C</i>	23	–
8	(-)-Xen D	20	–
8a	<i>epi(+)-Xen D</i>	15	–
8b	<i>ent(+)-Xen D</i>	17	–
8c	<i>ent-epi(-)-Xen D</i>	25	–

^aAfter silica gel column chromatography. ^bEnantiomeric excess (*ee*) was determined using specific optical rotation values reported for (-)-Xen A and B.¹³




Figure 1. Morphological analysis of the cytotoxic effects of (-)-Xen B at 0 and 19-25 μM on cancerous cell lines including human colon carcinoma (HCT-116), human lung carcinoma (H460), human ovarian carcinoma (OV-2008), human breast adenocarcinoma (MDA-MB-231), human prostate adenocarcinoma (DU-145) and normal human epithelial colon cell (CRL-1459). The cells were photographed at 20 $^{\circ}\text{C}$, 72 h after incubation for each triplicate treatment.

Table 4. Cytotoxic effects of naturally occurring Xens A-D and stereoisomers on the survival of cancer cell lines and normal cell lines.

Compounds	Colon	Lung	Ovarian	Breast	Prostate	Normal Cells	
	^a HCT-116	^a H460	^a OV-2008	^a MDA-MB-231	^a DU-145	^a CRL	^a CHO
(-)-Xen A	>100	>100	>100	95	>100	99	88
<i>epi(+)-Xen A</i>	81	95	72	>100	94	>100	>100
<i>ent(+)-Xen A</i>	86	97	65	88	98	>100	78
<i>ent-epi(-)-Xen A</i>	46	78	58	60	67	>100	87
(-)-Xen B	19	24	25	21	25	86	54
<i>epi(+)-Xen B</i>	48	67	59	55	67	63	78
<i>ent(+)-Xen B</i>	48	>100	>100	41	67	>100	87
<i>ent-epi(-)-Xen B</i>	25	58	60	20	42	87	59
(-)-Xen C	63	79	50	36	72	>100	92
<i>epi(+)-Xen C</i>	62	75	72	59	85	>100	92
<i>ent(+)-Xen C</i>	90	97	97	97	99	>100	>100

Journal Name

ARTICLE

<i>ent-epi-(-)-Xen C</i>	>100	>100	>100	>100	97	>100	>100
<i>(-)-Xen D</i>	99	>100	>100	>100	>100	>100	>100
<i>epi-(+)-Xen D</i>	54	79	64	49	85	76	88
<i>ent-(+)-Xen D</i>	26	35	25	21	50	>100	84
<i>ent-epi-(-)-Xen D</i>	35	81	64	64	90	72	88
^b Cisplatin	11	8	14	12	14	21	18

^aThe IC₅₀ (μM) values are represented as mean ± SD of three independent experiments performed in triplicate. ^bCisplatin was used as a positive control.

The Cytotoxicity Effects of Active (-)-Xen B and *ent-(+)-Xen D* on Various Cell Lines (Cancerous and Non-Cancerous Cells)

Based on our data, for (-)-Xen B and the cohort of stereoisomers, the chiral properties of C₈ containing the (*S*) stereo-configuration is considered a critical factor influencing compound potency. As summarized in **Table 4**, (-)-Xen B (highlighted in yellow) with (*S*) configuration at C₈, was determined to have excellent cytotoxic activities (IC₅₀ = 19 – 25 μM) against five cancer cell lines, and was determined to be approximately 2-fold more potent than its corresponding diastereomer, *epi-(+)-Xen B* with the (*R*) configuration at C₈. Coincident results were observed for *ent-epi-(-)-Xen B* and *ent-(+)-Xen B*, with IC₅₀ values of 20 – 60 μM and 41 – >100 μM, respectively. These results strongly suggest that the chirality at C₈ plays a substantial role in cytotoxic activity of (-)-Xen B stereoisomers.

Moreover, *ent-(+)-Xen D* (highlighted in yellow) was selectively active against three cancer cell lines, including HCT-116, MDA-MB-231 and OV-2008. In those three cancer cell lines, *ent-(+)-Xen D* with (*R*) configuration at C₁₁ revealed better cytotoxic effects than its diastereomer, *epi-(+)-Xen D*, with respective IC₅₀ values of 21 – 35 μM and 49 – >79 μM. Similar results were observed for *ent-epi-(-)-Xen D* and (-)-Xen D, proving that the stereochemistry of C₁₁ in (-)-Xen D plays an important role in cytotoxic activity.




Figure 2. (A) IC₅₀ values and (B) cell survival curves of cancer cells compared to that of normal human epithelial colon cell (CRL-1459) when treated with (-)-Xen B determined by the MTT assay. IC₅₀ values are represented as means ± SD of three independent experiments performed in triplicate.

Conclusion

In conclusion, a concise synthesis of natural Xen A-D and all subsequent stereoisomers has been achieved in a one-pot, two-step Ugi 4-CR synthetic strategy. In this reaction, chiral *N*-Boc protected amino acids (L-Leu/Val and D-Leu/Val), aryl isocyanides, phenyl acetaldehyde and methylamine were utilized as starting materials. All reactions were carried out efficiently and simple chromatographic purification led to

enantiomeric excesses (>90% *ee*) in reasonable yields. Based on our knowledge of the literature, the anticancer activities of sixteen Xen family of natural products and all their subsequent stereoisomers are reported here for the very first time. When dealing with biological interactions especially for medicinal applications, comparing the activity of stereoisomers is crucial, as biological targets are chiral. The stereo-SAR study demonstrated that only two compounds, among sixteen synthesized, were very active in the MTT assay. Natural (-)-

ARTICLE

Journal Name

Xen B revealed high cytotoxic activity against five tested cancer cell lines and *ent*-(+)-Xen D indicated decent cytotoxicity, selectively against three cancer cell lines, described in **Table 4**. Furthermore, SAR results indicated that the stereochemistry at C₈ and C₁₁ in (-)-Xen B and *ent*-(+)-Xen D, respectively, plays an important role in cytotoxic activities. Moreover, it should be noted that most of the compounds, especially those that are considerably active, were significantly less toxic toward normal cells, when compared to cancer cells, suggesting that the Xen analogues show selective toxic. Cisplatin, a well-known anticancer agent, was used as a positive control in our experiments and Xen were more selective compared to cisplatin on normal cells. Finally, the results suggest that the stereochemistry of Xens could possibly play a vital role in the enhancement of bioactivity. Therefore, finding the target binding site should reveal more information about the connection between chiral properties and bioactivity of Xens in the future.^{35, 36}

Experimental

Methods and Materials

Chemistry

All reagents and solvents purchased were used without further purification unless otherwise stated. Reaction progress was monitored using thin layer chromatography (TLC). TLC was visualized using UV. Column chromatography was performed using Whatman Purasil 60 A (230–400 mesh ASTM) silica gel; yields refer to chromatographically and spectroscopically pure compounds. ¹H and ¹³C NMR were recorded using a Bruker Avance III 600 spectrometer at 22 °C (default) unless otherwise noted. The residual solvent signal in CD₃OD was referenced to 3.31 and 49.0 ppm in proton and carbon spectra respectively. Signal patterns are indicated as s: singlet; d: doublet; t: triplet; q: quartet; m: multiplet; dd: doublet of doublets; br: broad and coupling constants are reported in hertz (Hz). Low resolution mass spectra (LRMS) were acquired on an Esquire-LC electrospray ionization (ESI) mass spectrometer. High resolution mass spectra (HRMS) were obtained with a Bruker Maxis 4G mass spectrometer.

General Procedure

To 0.27 mL (1.66 mmol) of methylamine (33% in ethanol) (**3**) in 15 mL methanol, was added 0.18 mL (1.66 mmol) phenyl acetaldehyde (**2**), and the reaction was allowed to stir for 5 minutes at room temperature. Then, 1.66 mmol of corresponding carboxylic acid **4a-b**, and 1.66 mmol of isocyanide **1a-b** were added sequentially and the reaction was continuously stirred until no noticeable starting reagents were visualized on TLC. Upon completion of the reaction, methanol was evaporated under reduced pressure. After obtaining mass of the unpurified Boc-protected product, the material was dissolved in CH₂Cl₂ (1 mL) and trifluoroacetic acid (1 mL) was added as the reaction mixture was allowed to chill in an ice-

bath for 2 h. The reaction was monitored for completion by TLC and the contents were then concentrated under reduced pressure. The crude compound was then subjected to flash column chromatography (EtOAc/Hexanes) to yield pure compounds **5-8 (a-c)**.

(S)-N,4-dimethyl-2-(methylamino)-N-((S)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)pentanamide (**5**)

The compound was obtained as a white solid; yield: (185.01 mg, 27%); [α]_D²⁰ = -57 (c 0.2, MeOH); lit.¹³ = -54 (c 0.2, MeOH); ¹H NMR (600 MHz, CD₃OD) showed the presence of two rotamers in a ratio of 4.3/1; major rotamer noted: δ 7.29-7.24 (m, 6H, aryl), 7.21-7.17 (m, 4H, aryl), 5.42-5.39 (dd, *J*₁ = 6.0 Hz, *J*₂ = 12.0 Hz, 1H, CH), 3.43-3.41 (t, *J* = 7.2 Hz, 2H, CH₂), 3.38-3.36 (m, 1H, CH), 3.18-3.03 (dd, *J*₁ = 5.4 Hz, *J*₂ = 14.4 Hz, 1H, CH), 3.11-3.00 (m, 1H, CH), 2.97 (s, 3H, CH₃-N), 2.78-2.76 (t, *J* = 7.2 Hz, 2H, CH₂), 1.74 (s, 3H, CH₃-NH), 1.30-1.25 (m, 2H, CH₂), 1.15-1.14 (m, 1H, CH), 0.92-0.89 (m, 6H, 2CH₃); ¹³C NMR (150 MHz, CD₃OD) major rotamer noted: δ 175.84, 170.75, 138.97, 137.13, 128.87, 128.74, 128.51, 128.14, 126.34, 126.01, 58.01, 57.57, 42.04, 40.46, 35.04, 34.22, 32.72, 30.70, 24.24, 22.49, 20.97 ppm; HRMS (TOF-ESI): [M+H]⁺calculated for C₂₅H₃₆N₃O₂: 410.2808; found: 410.2807.

(S)-N,4-dimethyl-2-(methylamino)-N-((R)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)pentanamide (**5a**)

The compound was obtained as a white solid; yield: (127.59 mg, 18%); [α]_D²⁰ = +43 (c 0.2, MeOH); ¹H NMR (600 MHz, CD₃OD); δ 7.28-7.20 (m, 10H, aryl), 5.54-5.51 (dd, *J*₁ = 6.0 Hz, *J*₂ = 12.0 Hz, 1H, aryl), 3.77-3.75 (m, 1H, CH), 3.48-3.44 (m, 2H, CH₂), 3.31-3.25 (dd, *J*₁ = 6.0 Hz, *J*₂ = 12.0 Hz, 1H, CH₂), 3.00-2.92 (m, 4H, CH, CH₃-N), 2.82-2.80 (t, *J* = 6.0 Hz, 2H, CH₂), 2.37 (s, 3H, CH₃-NH), 1.10-1.07 (m, 2H, CH₂), 0.89-0.85 (m, 1H, CH), 0.74-0.73 (d, *J* = 6.0 Hz, 3H, CH₃), 0.69-0.68 (d, *J* = 6.0 Hz, 3H, CH₃); ¹³C NMR (150 MHz, CD₃OD) major rotamer noted: δ 174.85, 170.78, 138.98, 136.87, 128.49, 128.45, 128.20, 128.13, 126.55, 126.02, 57.45, 57.21, 41.03, 40.56, 35.01, 34.35, 32.61, 30.46, 23.83, 21.92, 21.33 ppm; HRMS (TOF-ESI): [M+H]⁺calculated for C₂₅H₃₆N₃O₂: 410.2808; found: 410.2820.

(R)-N,4-dimethyl-2-(methylamino)-N-((R)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)pentanamide (**5b**)

The compound was obtained as a white solid; yield: (102.30 mg, 15%); [α]_D²⁰ = +57 (c 0.2, MeOH); ¹H NMR (600 MHz, CD₃OD) showed the presence of two rotamers in a ratio of 3.5/1; major rotamer noted: δ 7.28-7.21 (m, 6H, aryl), 7.19-7.16 (m, 4H, aryl), 5.43-5.40 (dd, *J*₁ = 6.0 Hz, *J*₂ = 12.0 Hz, 1H, CH), 3.44-3.36 (t, *J* = 7.2 Hz, 2H, CH₂), 3.35-3.33 (m, 1H), 3.20-3.17 (dd, *J*₁ = 5.2 Hz, *J*₂ = 14.3 Hz, 1H), 3.01-2.96 (m, 4H, CH, CH₃-N), 2.78-2.76 (t, *J* = 7.2 Hz, 2H, CH₂), 1.73 (s, 3H, CH₃-NH), 1.29-1.24 (m, 2H, CH₂), 1.14-1.13 (m, 1H, CH), 0.91-0.88 (m, 6H, 2CH₃); ¹³C NMR (150 MHz, CD₃OD) major rotamer noted: δ 176.00, 170.75, 139.04, 137.48, 128.88, 128.74, 128.52, 126.60, 126.34, 126.07, 58.01, 57.99, 56.22, 40.47, 35.09, 34.24, 32.80, 30.71, 24.24, 21.95, 21.01 ppm; HRMS (TOF-ESI): [M+H]⁺calculated for C₂₅H₃₆N₃O₂: 410.2808; found: 410.2823.

(R)-N,4-dimethyl-2-(methylamino)-N-((S)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)pentanamide (5c)

The compound was obtained as a white solid; yield: (133.02 mg, 19%); $[\alpha]_{\text{D}}^{20} = -43$ (c 0.2, MeOH); $^1\text{H NMR}$ (600 MHz, CD_3OD); $\delta = 7.29$ -7.17 (m, 10H, aryl), 5.55-5.52 (dd, $J_1 = 5.3$ Hz, $J_2 = 12.0$ Hz, 1H, CH), 3.46-3.40 (m, 2H, CH_2), 3.39-3.38 (m, 1H, CH), 3.25-3.22 (dd, $J_1 = 5.3$ Hz, $J_2 = 12.0$ Hz, 1H, CH), 2.98-2.93 (m, 4H, CH, CH_3 -N), 2.81-2.78 (m, 2H, CH_2), 2.20 (s, 3H, CH_3 -NH), 0.99-0.95 (m, 1H, CH), 0.83-0.78 (m, 1H, CH), 0.77-0.74 (m, 1H, CH), 0.75 (d, $J = 6.0$ Hz, 3H, CH_3), 0.66 (d, $J = 6.0$ Hz, 3H, CH_3) ppm; $^{13}\text{C NMR}$ (150 MHz, CD_3OD): δ 176.43, 170.89, 138.99, 136.95, 128.49, 128.47, 128.21, 128.16, 126.47, 126.01, 57.36, 57.19, 41.74, 40.53, 35.03, 34.32, 33.11, 30.41, 23.91, 21.99, 21.49 ppm; **HRMS** (TOF-ESI): $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{25}\text{H}_{36}\text{N}_3\text{O}_2$: 410.2808; found: 410.2816.

(S)-N-((S)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,4-dimethyl-2-(methylamino)pentanamide (6)

The compound was obtained as a yellowish solid; yield: (215.77 mg, 28%); $[\alpha]_{\text{D}}^{20} = -56$ (c 0.3, MeOH); lit.¹³ -58 (c 0.3, MeOH); $^1\text{H NMR}$ (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 2.8/1; major rotamer noted: δ 7.56-7.55 (d, $J = 6.0$ Hz, 1H, aryl), 7.33-7.32 (d, $J = 6.0$ Hz, 1H, aryl), 7.26-7.23 (m, 4H, aryl), 7.19-7.16 (m, 1H, aryl), 7.08-7.06 (t, $J = 7.2$ Hz, 1H, aryl), 7.04-6.99 (m, 2H, aryl), 5.40-5.39 (dd, $J_1 = 6.0$, $J_2 = 12.0$ Hz, 1H, CH), 3.57-3.50 (m, 2H, CH_2), 3.36-3.35 (m, 1H, CH), 3.17-3.15 (dd, $J_1 = 5.4$ Hz, $J_2 = 14.4$ Hz, 1H, CH), 3.01-2.95 (m, 6H, CH, CH_2 , CH_3 -N), 1.73 (s, 3H, CH_3 -NH), 1.37-1.21 (m, 2H, CH_2), 1.07-1.06 (m, 1H, CH), 0.98-0.84 (m, 6H, 2 CH_3) ppm; $^{13}\text{C NMR}$ (150 MHz, CD_3OD) major rotamer noted: δ 175.72, 170.68, 136.78, 128.74, 128.43, 128.13, 127.39, 126.32, 121.05, 120.96, 118.23, 117.88, 111.61, 110.89, 58.17, 57.56, 39.84, 39.77, 32.67, 30.77, 30.64, 24.77, 24.26, 22.41, 20.98 ppm; **HRMS** (TOF-ESI): $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{27}\text{H}_{37}\text{N}_4\text{O}_2$: 449.2917 found 449.2933.

(S)-N-((R)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,4-dimethyl-2-(methylamino)pentanamide (6a)

The compound was obtained as a yellowish solid; yield: (142.97 mg, 19%); $[\alpha]_{\text{D}}^{20} = +26^\circ$ (c 0.3, MeOH); $^1\text{H NMR}$ (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 2.68/1; major rotamer noted: δ 7.57-7.56 (d, $J = 7.8$ Hz, 1H, aryl), 7.33-7.31 (d, $J = 7.8$ Hz, 1H, aryl), 7.25-7.20 (m, 4H, aryl), 7.19-7.17 (t, $J = 7.2$ Hz, 1H, aryl), 7.09-7.06 (m, 2H, aryl), 7.02-7.01 (t, $J = 7.8$ Hz, 1H, aryl), 5.54-5.51 (dd, $J_1 = 5.4$ Hz, $J_2 = 11.4$ Hz, 1H, CH), 3.55-3.52 (m, 2H, CH_2), 3.40-3.37 (m, 1H, CH), 3.17-3.15 (dd, $J_1 = 5.4$, $J_2 = 15.0$ Hz, 1H, CH), 2.99-2.94 (m, 3H, CH, CH_2), 2.88 (s, 3H, CH_3 -N), 2.21 (s, 3H, CH_3 -NH), 0.96-0.95 (m, 2H, CH_2), 0.84-0.79 (m, 1H, CH_2), 0.80-0.69 (d, $J = 6.0$ Hz, 3H, CH_3), 0.65-0.64 (d, $J = 6.0$ Hz, 3H, CH_3) ppm; $^{13}\text{C NMR}$ (150 MHz, CD_3OD) major rotamer noted: δ 176.17, 170.78, 136.95, 136.77, 128.65, 128.16, 127.42, 126.46, 122.17, 120.96, 118.23, 117.91, 111.58, 110.86, 57.45, 57.19, 41.58, 39.87,

34.13, 30.34, 30.25, 24.63, 24.34, 22.47, 21.42 ppm; **HRMS** (TOF-ESI): $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{27}\text{H}_{37}\text{N}_4\text{O}_2$: 449.2917 found 449.2931.

(R)-N-((R)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,4-dimethyl-2-(methylamino)pentanamide (6b)

The compound was obtained as a yellowish solid; yield: (151.63 mg, 20%); $[\alpha]_{\text{D}}^{20} = +56$ (c 0.3, MeOH); $^1\text{H NMR}$ (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 2.7/1; major rotamer noted: δ 7.56-7.55 (m, 1H, aryl), 7.33-7.17 (m, 4H, aryl), 7.09-7.00 (m, 5H, aryl), 5.41-5.39 (dd, $J_1 = 5.6$, $J_2 = 11.0$ Hz, 1H, CH), 3.52-3.50 (m, 2H, CH_2), 3.34-3.32 (m, 1H, CH), 3.19-3.15 (dd, $J_1 = 5.6$ Hz, $J_2 = 14.4$ Hz, 1H, CH), 3.00-2.91 (m, 6H, CH, CH_2 , CH_3 -N), 1.69 (s, 3H, CH_3 -NH), 1.29-1.20 (m, 2H), 1.07-1.06 (m, 1H, CH), 0.86-0.84 (m, 6H, 2 CH_3) ppm; $^{13}\text{C NMR}$ (150 MHz, CD_3OD) major rotamer noted: δ 176.03, 170.71, 137.19, 128.85, 128.42, 128.12, 127.38, 126.31, 122.07, 120.95, 118.23, 117.87, 110.96, 110.89, 61.43, 57.57, 43.08, 39.83, 34.08, 32.74, 30.63, 24.77, 24.27, 22.42, 20.99 ppm; **HRMS** (TOF-ESI): $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{27}\text{H}_{37}\text{N}_4\text{O}_2$: 449.2917 found 449.2914.

(R)-N-((S)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,4-dimethyl-2-(methylamino)pentanamide (6c)

The compound was obtained as a yellowish solid; yield: (212.30 mg, 28%); $[\alpha]_{\text{D}}^{20} = -26$ (c 0.3, MeOH); $^1\text{H NMR}$ (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 6.0/1; major rotamer noted: $\delta = 7.57$ -7.56 (d, $J = 7.8$ Hz, 1H, aryl), 7.33-7.31 (d, $J = 7.8$ Hz, 1H, aryl), 7.25-7.17 (m, 5H, aryl), 7.10-7.07 (m, 2H, aryl), 7.02-7.01 (t, $J = 7.8$ Hz, 1H, aryl), 5.54-5.52 (dd, $J_1 = 4.32$ Hz, $J_2 = 11.0$ Hz, 1H, CH), 3.54-3.36 (m, 2H, CH_2), 3.35-3.31 (m, 1H), 3.23-3.20 (dd, $J_1 = 5.4$, $J_2 = 15.0$ Hz, 1H, CH), 2.99-2.94 (m, 3H, CH, CH_2), 2.88 (s, 3H, CH_3 -N), 2.21 (s, 3H, CH_3 -NH), 0.96-0.93 (m, 2H, CH_2), 0.84-0.79 (m, 1H, CH), 0.80-0.69 (d, $J = 6.0$ Hz, 3H, CH_3), 0.65-0.64 (d, $J = 6.0$ Hz, 3H, CH_3) ppm; $^{13}\text{C NMR}$ (150 MHz, CD_3OD) major rotamer noted: δ 176.40, 170.82, 136.99, 136.78, 128.66, 128.14, 127.42, 126.44, 122.17, 120.95, 118.22, 117.90, 111.58, 110.85, 57.40, 57.15, 41.72, 39.84, 34.14, 32.98, 30.29, 24.63, 23.89, 21.96, 21.46; **HRMS** (TOF-ESI): $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{27}\text{H}_{37}\text{N}_4\text{O}_2$: 449.2917 found 449.2931.

(S)-N,3-dimethyl-2-(methylamino)-N-((S)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)butanamide (7)

The compound was obtained as a white solid; yield: (166.99 mg, 25%); $[\alpha]_{\text{D}}^{20} = -54$ (c 0.2, MeOH); $^1\text{H NMR}$ (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 7.70/1; major rotamer noted: δ 7.29-7.27 (m, 6H, aryl), 7.22-7.7.19 (m, 4H, aryl), 5.51-5.49 (dd, $J_1 = 5.4$ Hz, $J_2 = 11.4$ Hz, 1H, CH), 3.50-3.44 (t, $J = 7.2$ Hz, 2H, CH_2), 3.22-2.99 (m, 6H, CH, CH_2 , CH_3 -N), 2.07-2.04 (m, 1H, CH), 1.97 (s, 3H, CH_3 -NH), 1.04-1.03 (d, $J = 6.6$ Hz, 3H, CH_3), 0.98-0.97 (d, $J = 6.6$ Hz, 3H, CH_3) ppm; $^{13}\text{C NMR}$ (150 MHz, CD_3OD) major rotamer noted: δ 170.13, 167.65, 138.92, 136.91, 128.46, 128.23, 128.18, 128.13,

126.54, 126.03, 63.45, 58.06, 40.44, 34.98, 34.97, 34.05, 31.17, 29.81, 17.67, 16.10 ppm; **HRMS** (TOF-ESI): $[M+H]^+$ calculated for $C_{24}H_{34}N_3O_2$: 396.2651; found: 396.2645.

(S)-N,3-dimethyl-2-(methylamino)-N-((R)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)butanamide (7a)

The compound was obtained as a white solid; yield: (129.45 mg, 19%); $[\alpha]_D^{20} = +29$ (c 0.2, MeOH); 1H NMR (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 2.96/1; major rotamer noted: δ 7.29-7.26 (m, 6H, aryl), 7.22-7.20 (m, 4H, aryl), 5.55-5.49 (dd, $J_1 = 5.4$ Hz, $J_2 = 12.0$ Hz, 1H, CH), 3.50-3.46 (m, 2H, CH_2), 3.27-3.23 (m, 2H, CH_2), 3.02-2.98 (m, 4H, CH, CH_3-N), 2.83-2.81 (t, $J = 7.2$ Hz, 2H, CH_2), 2.48 (s, 3H, CH_3-NH), 1.66-1.59 (m, 1H, CH), 0.75-0.74 (d, $J = 6.6$ Hz, 3H, CH_3), 0.53-0.52 (d, $J = 6.6$ Hz, 3H, CH_3) ppm; ^{13}C NMR (150 MHz, CD_3OD) major rotamer noted: δ 170.53, 170.19, 138.98, 136.79, 128.52, 128.50, 128.34, 128.14, 126.60, 126.04, 63.97, 57.91, 40.59, 34.99, 34.28, 30.76, 29.51, 17.47, 15.66, 13.04 ppm; **HRMS** (TOF-ESI): $[M+H]^+$ calculated for $C_{24}H_{34}N_3O_2$: 396.2651; found: 396.2640.

(R)-N,3-dimethyl-2-(methylamino)-N-((R)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)butanamide (7b)

The compound was obtained as a white solid; yield: (142.68 mg, 21%); $[\alpha]_D^{20} = +54$ (c 0.2, MeOH); 1H NMR (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 4.2/1; major rotamer noted: δ 7.29-7.23 (m, 6H, aryl), 7.20-7.17 (m, 4H, aryl), 5.51 (d.d, $J_1 = 5.4$, $J_2 = 10.8$ Hz, 1H, CH), 3.44 (t, $J = 6.6$ Hz, 2H, CH_2), 3.22-3.21 (m, 2H, 2CH), 3.00-2.96 (m, 4H, CH, CH_3-N), 2.78-2.75 (m, 2H, CH_2), 1.71-1.66 (m, 4H, CH, CH_3-NH), 0.92-0.88 (m, 6H, 2 CH_3); ^{13}C NMR (150 MHz, CD_3OD) major rotamer noted: δ 175.55, 170.46, 138.98, 137.03, 128.97, 128.63, 128.48, 128.19, 128.13, 126.38, 64.42, 57.52, 40.51, 35.03, 34.31, 33.65, 30.50, 30.28, 18.37, 16.24; **HRMS** (TOF-ESI): $[M+H]^+$ calculated for $C_{24}H_{34}N_3O_2$: 396.2651; found: 396.2644.

(R)-N,3-dimethyl-2-(methylamino)-N-((S)-1-oxo-1-(phenethylamino)-3-phenylpropan-2-yl)butanamide (7c)

The compound was obtained as a white solid; yield: (156.95 mg, 23%); $[\alpha]_D^{20} = -29$ (c 0.2, MeOH); 1H NMR (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 6.3/1; major rotamer noted: δ 7.29-7.23 (m, 7H, aryl), 7.20-7.17 (m, 3H, aryl), 5.51 (d.d, $J_1 = 5.4$, $J_2 = 10.8$ Hz, 1H, CH), 3.44 (t, $J = 6.6$ Hz, 2H, CH_2), 3.22-3.21 (m, 2H, CH_2), 2.99-2.93 (m, 4H, CH, CH_3-N), 2.83-2.77 (m, 2H, CH_2), 2.17 (s, 3H, CH_3-NH), 1.40-1.36 (1H, m, CH), 0.63 (d, $J = 6.6$ Hz, 3H, CH_3), 0.53 (d, $J = 6.6$ Hz, 3H, CH_3); ^{13}C NMR (150 MHz, CD_3OD) major rotamer noted: δ 175.55, 170.46, 138.98, 137.03, 128.97, 128.63, 128.48, 128.19, 128.13, 126.38, 64.42, 57.52, 40.51, 35.03, 34.31, 33.65, 30.50, 30.28, 18.37, 16.24; **HRMS** (TOF-ESI): $[M+H]^+$ calculated for $C_{24}H_{34}N_3O_2$: 396.2651; found: 396.2644.

(S)-N-((S)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,3-dimethyl-2-(methylamino)butanamide (8)

The compound was obtained as a yellowish solid; yield: (142.02 mg, 20%); $[\alpha]_D^{20} = -58$ (c 0.3, MeOH); 1H NMR (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 3.8/1; major rotamer noted: δ 7.55-7.54 (d, $J = 7.8$ Hz, 1H, aryl), 7.33-7.31 (d, $J = 7.8$ Hz, 1H, aryl), 7.23-7.18 (m, 4H, aryl), 7.16-7.15 (m, 1H, aryl), 7.09-7.08 (t, $J = 7.2$ Hz, 1H, aryl), 7.04 (s, 1H, aryl), 6.99 (t, $J = 7.2$ Hz, 1H, aryl), 5.47 (dd, $J_1 = 6.0$ Hz, $J_2 = 10.8$ Hz, 1H, CH), 3.52-3.50 (m, 2H, CH_2), 3.18-3.14 (m, 1H, CH), 3.10-3.08 (d, $J = 6.0$ Hz, 1H, CH), 2.99-2.91 (m, 6H, CH, CH_2 , CH_3-N), 1.68 (s, 3H, CH_3-NH), 1.60-1.57 (m, 1H, CH), 0.84-0.83 (d, $J = 6.6$ Hz, 3H, CH_3), 0.81 (d, $J = 6.6$ Hz, 3H, CH_3) ppm; ^{13}C NMR (150 MHz, CD_3OD) major rotamer noted: δ 175.35, 170.66, 137.15, 136.80, 128.72, 128.35, 128.11, 126.30, 122.07, 120.95, 118.22, 117.87, 111.50, 110.86, 64.47, 57.65, 39.64, 34.03, 33.03, 30.93, 30.57, 24.79, 18.55, 16.40 ppm; **HRMS** (TOF-ESI): $[M+H]^+$ calculated for $C_{26}H_{35}N_4O_2$: 435.2760; found: 435.2754.

(S)-N-((R)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,3-dimethyl-2-(methylamino)butanamide (8a)

The compound was obtained as a white solid; yield: (109.67 mg, 15%); $[\alpha]_D^{20} = +28$ (c 0.3, MeOH); 1H NMR (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 6.6/1; major rotamer noted: δ 7.56-7.55 (d, $J = 7.8$ Hz, 1H, aryl), 7.33-7.32 (d, $J = 7.8$, 1H, aryl), 7.24-7.21 (m, 4H, aryl), 7.17-7.7.15 (m, 1H, aryl), 7.09-7.08 (t, $J = 7.2$ Hz, 1H, aryl), 7.05 (s, 1H, aryl), 7.01-6.99 (t, $J = 7.2$ Hz, 1H, aryl), 5.52-5.49 (dd, $J_1 = 5.4$ Hz, $J_2 = 11.4$ Hz, 1H, CH), 3.53-3.51 (t, $J = 6.6$ Hz, 2H, CH_2), 3.22-3.18 (m, 2H, CH_2), 2.96-2.90 (m, 6H, CH, CH_2 , CH_3-N), 2.08 (s, 3H, CH_3-NH), 1.36-1.29 (m, 1H, CH), 0.62-0.60 (d, $J = 6.6$ Hz, 3H, CH_3), 0.51-0.50 (d, $J = 6.6$ Hz, 3H, CH_3) ppm; ^{13}C NMR (150 MHz, CD_3OD) major rotamer noted: δ 175.36, 170.85, 137.06, 136.78, 128.62, 128.17, 127.39, 126.36, 122.15, 120.96, 118.23, 117.89, 110.43, 110.86, 64.38, 57.60, 39.79, 33.38, 33.49, 30.49, 30.25, 24.66, 18.32, 16.21 ppm; **HRMS** (TOF-ESI): $[M+H]^+$ calculated for $C_{26}H_{35}N_4O_2$: 435.2760 found 435.2775.

(R)-N-((R)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,3-dimethyl-2-(methylamino)butanamide (8b)

The compound was obtained as a yellowish solid; yield: (121.13 mg, 17%); $[\alpha]_D^{20} = +58$ (c 0.3, MeOH); 1H NMR (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 3.2/1; major rotamer noted: δ 7.55 (d, $J = 7.8$ Hz, 1H, aryl), 7.32 (d, $J = 7.8$ Hz, 1H, aryl), 7.24-7.22 (m, 1H, aryl), 7.18-7.15 (m, 1H, aryl), 7.08 (t, $J = 7.8$ Hz, 1H, aryl), 7.04-7.00 (m, 1H, aryl), 5.48 (d.d, $J_1 = 5.4$, $J_2 = 11.4$ Hz, 1H, CH), 3.53-3.50 (m, 2H, CH_2), 3.17-3.12 (m, 2H, CH_2), 2.99-2.92 (m, 6H, CH, CH_2 , CH_3-N), 1.70 (s, 3H, CH_3-NH), 1.62-1.58 (m, 1H, CH), 0.90 (d, $J = 7.2$ Hz, 3H, CH_3), 0.82 (d, $J = 7.2$ Hz, 3H, CH_3); ^{13}C NMR (150 MHz, CD_3OD) major rotamer noted: δ 171.43, 170.64, 137.15, 136.80, 128.73, 128.11, 127.37, 126.30, 121.05, 120.95, 118.22, 117.87, 111.51, 110.86, 64.45, 57.66, 39.64, 34.09, 32.99, 30.89, 30.58, 24.79, 18.57, 16.67; **HRMS** (TOF-ESI): $[M+H]^+$ calculated for $C_{26}H_{35}N_4O_2$: 435.2760; found: 435.2755.

(R-N-((S)-1-((2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-yl)-N,3-dimethyl-2-(methylamino)butanamide (8c)

The compound was obtained as a white solid; yield: (182.30 mg, 25%); $[\alpha]_D^{20} = -28$ (c 0.3, MeOH); $^1\text{H NMR}$ (600 MHz, CD_3OD) showed the presence of two rotamers in a ratio of 5.9/1; major rotamer noted: δ 7.56-7.54 (d, $J = 7.8$ Hz, 1H, aryl), 7.33-7.31 (d, $J = 7.8$ Hz, 1H, aryl), 7.22-7.20 (m, 4H, aryl), 7.17-7.15 (m, 1H, aryl), 7.08-7.07 (t, $J = 7.8$ Hz, 1H, aryl), 7.05 (s, 1H, aryl), 7.02-7.01 (m, 1H, aryl), 5.52-5.49 (d.d, $J_1 = 6.0$, $J_2 = 12.0$ Hz, 1H, CH), 3.53-3.51 (t, $J = 7.2$ Hz, 2H, CH_2), 3.21-3.18 (d.d, $J_1 = 3.6$, $J_2 = 15.0$ Hz, 1H, CH), 3.15-3.14 (d, $J = 5.4$, 1H, CH), 2.96-2.93 (m, 3H, CH, CH_2), 2.88 (s, 3H, $\text{CH}_3\text{-N}$), 2.07 (s, 3H, $\text{CH}_3\text{-NH}$), 1.34-1.33 (m, 1H, CH), 0.60 (d, $J = 6.6$ Hz, 3H, CH_3), 0.50 (d, $J = 6.6$ Hz, 3H, CH_3); $^{13}\text{C NMR}$ (150 MHz, CD_3OD) major rotamer noted: δ 175.59, 170.86, 137.79, 128.63, 128.52, 128.17, 127.40, 126.35, 122.16, 120.97, 118.25, 117.91, 111.58, 110.88, 64.41, 57.60, 39.80, 34.13, 33.55, 30.44, 30.29, 24.68, 18.37, 16.25; **HRMS** (TOF-ESI): $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{26}\text{H}_{35}\text{N}_4\text{O}_2$: 435.2760; found: 435.2726.

Biology**Materials**

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Calbiochem EMD Millipore (Billerica, MA, USA). Dulbecco's modification of Eagle's medium (DMEM) and 0.25% trypsin + 2.20 mM ethylenediaminetetraacetic acid (EDTA), phosphate buffered saline (PBS without calcium or magnesium), and DMEM (phenol red - free) were purchased from Mediatech, Inc. (Corning subsidiaries, Manassas, VA, USA). Fetal Bovine Serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA, USA). Penicillin/streptomycin was purchased from Lonza, Inc. (Allendale NJ, USA). Dimethyl sulfoxide (DMSO) was purchased from VWR Analytical (Radnor, PA, USA).

Cell Lines and Culture

Cancer cells, including colon (HCT-116), lung (H460), ovarian (OV-2008), breast (MDA-MB-231), prostate (DU-145), and normal cell lines including human epithelial colon (CRL-1459) and Chinese hamster ovary (CHO) were used in this study. All the cell lines were grown as adherent monolayers in flasks with DMEM cultured media supplemented with 10% FBS and 1% streptomycin/penicillin in a humidified incubator with 5% CO_2 at 37°C.

Cell Cytotoxicity Assays by MTT

To determine the cytotoxicity of the natural Xens A-D and all stereoisomers thereof, a (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) MTT colorimetric assay was used, as previously described.³⁷ Briefly, after harvesting the cells with 0.25% trypsin and 2.21 mM EDTA, 1X, cancer cell lines were re-suspended in DMEM. Cells were seeded evenly (180 μL /well) into 96 well-plates in triplicate at 5000 cells/well and the plates were returned to the incubator, allowing cells to attach to the wells, for up to 24 h. On the second day of the

experiment, various concentrations of each compound ranging from 0.10 to 100.0 μM (20.0 μL /well) were added to the wells. After 72 h of incubation, 20.0 μL of the MTT solution (4.0 mg/mL) was added to each well. The plates were further incubated for 4 h to allow the viable cells to bio transform the yellow-colored MTT into dark-blue formazan crystals. The medium was discarded and 100.0 μL of DMSO was used to dissolve the formazan crystals. The absorbance was measured at 570 nm using the SpectraMax® iD3 H1 Multi-Mode Micro Reader from Molecular Devices (Sunnyvale, CA, USA). The IC_{50} values were calculated from the cell survival percentages. Similarly, the cytotoxicity of the test compounds was compared to normal cell lines CHO and CRL-1459.

Cell Morphological Analysis

Cell images were taken using Evos® FL cell imaging system microscope from Thermo- Fisher Scientific (Waltham, MA) with a fluorescent lamp and digital camera. Morphological changes were observed in cancer and normal cell lines 72 h after incubation with different concentrations of Xen compounds.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

The authors gratefully acknowledge the University of Toledo for generous support of this project.

References

1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent and A. Jemal, *CA: A Cancer. J. Clin.*, 2015, **65**, 87-108.
2. X.-J. Liang, C. Chen, Y. Zhao and P. C. Wang, *Methods Mol. Biol.*, 2010, **596**, 467-488.
3. J. I. Hare, T. Lammers, M. B. Ashford, S. Puri, G. Storm and S. T. Barry, *Adv. Drug Delivery Rev.*, 2017, **108**, 25-38.
4. M. Greenwell and P. Rahman, *Int. J. Pharm. Sci. Res.*, 2015, **6**, 4103-4112.
5. Y. Lu, J. Yang and E. Sega, *The AAPS J.*, 2006, **8**, E466-E478.
6. C. Foley, A. Shaw and C. Hulme, *Org. Lett.*, 2016, **18**, 4904-4907.
7. R. J. Boohaker, M. W. Lee, P. Vishnubhotla, J. M. Perez and A. R. Khaled, *Curr. Med. Chem.*, 2012, **19**, 3794-3804.
8. S.-Y. Ehsan, R. P. Matthew and M. Josef, *Curr. Med. Chem.*, 2014, **21**, 1618-1630.
9. J. Thundimadathil, *J. Amino Acids*, 2012, **2012**, 13.
10. L. J. Zhang, X. Zhang, Z. S. You, H. Li, T. Feng and W. L. Wang, *Cat. Lett.*, 2016, **146**, 2081-2086.
11. A. L. Demain and P. Vaishnav, *Microb. Biotechnol.*, 2011, **4**, 687-699.
12. A. A. Stierle and D. B. Stierle, *Nat. Prod. Commun.*, 2015, **10**, 1671-1682.
13. G. Lang, T. Kalvelage, A. Peters, J. Wiese and J. F. Imhoff, *J. Nat. Prod.*, 2008, **71**, 1074-1077.

ARTICLE

Journal Name

14. D. Reimer, F. I. Nollmann, K. Schultz, M. Kaiser and H. B. Bode, *J. Nat. Prod.*, 2014, **77**, 1976-1980.
15. J. M. Crawford, C. Portmann, R. Kontrik, C. T. Walsh and J. Clardy, *Org. Lett.*, 2011, **13**, 5144-5147.
16. M. Shi, K. A. Kleski, K. R. Trabbic, J.-P. Bourgault and P. R. Andreana, *J. Am. Chem. Soc.*, 2016, **138**, 14264-14272.
17. S. Nishat and P. Andreana, *Vaccines*, 2016, **4**, 19.
18. K. R. Trabbic, J.-P. Bourgault, M. Shi, M. Clark and P. R. Andreana, *Org. Biomol. Chem.*, 2016, **14**, 3350-3355.
19. K. R. Trabbic, R. A. De Silva and P. R. Andreana, *MedChemComm*, 2014, **5**, 1143-1149.
20. T. Tanino, S. Ichikawa, M. Shiro and A. Matsuda, *J. Org. Chem.*, 2010, **75**, 1366-1377.
21. A. L. Brown, Q. I. Churches and C. A. Hutton, *J. Org. Chem.*, 2015, **80**, 9831-9837.
22. A. Plant, P. Thompson and D. M. Williams, *J. Org. Chem.*, 2009, **74**, 4870-4873.
23. J. P. Bourgault, A. R. Maddirala and P. R. Andreana, *Org. Biomol. Chem.*, 2014, **12**, 8125-8127.
24. A. A. Grolla, V. Podestà, M. G. Chini, S. Di Micco, A. Vallario, A. A. Genazzani, P. L. Canonico, G. Bifulco, G. C. Tron, G. Sorba and T. Pirali, *J. Med. Chem.*, 2009, **52**, 2776-2785.
25. X. Zhao, X. Liu, H. Mei, J. Guo, L. Lin and X. Feng, *Angewandte Chem. Int. Ed.*, 2015, **54**, 4032-4035.
26. F. Kolundžić, A. Murali, P. Pérez-Galán, J. O. Bauer, C. Strohmman, K. Kumar and H. Waldmann, *Angewandte Chem. Int. Ed.*, 2014, **53**, 8122-8126.
27. W. Goldeman and A. Nasulewicz-Goldeman, *Tetrahedron*, 2015, **71**, 3282-3289.
28. M. Ingold, G. V. López and W. Porcal, *ACS Sustainable Chem. Eng.*, 2014, **2**, 1093-1097.
29. I. Ugi, B. Werner and A. Dömling, *Molecules*, 2003, **8**, 53.
30. R. M. I. Ugi, U. Fetzer, C. Steinbrückner, *Angew. Chem.*, 1959, **71**, 386-388.
31. C. D. Turner and M. A. Ciufolini, *Org. Lett.*, 2012, **14**, 4970-4973.
32. M. Stucchi, S. Cairati, R. Cetin-Atalay, M. S. Christodoulou, G. Grazioso, G. Pescitelli, A. Silvani, D. C. Yildirim and G. Lesma, *Org. Biomol. Chem.*, 2015, **13**, 4993-5005.
33. L. Lan, C. Appelman, A. R. Smith, J. Yu, S. Larsen, R. T. Marquez, H. Liu, X. Wu, P. Gao, A. Roy, A. Anbanandam, R. Gowthaman, J. Karanicolas, R. N. De Guzman, S. Rogers, J. Aubé, M. Ji, R. S. Cohen, K. L. Neufeld and L. Xu, *Mol. Oncol.*, 2015, **9**, 1406-1420.
34. C. Karthikeyan, P. Jharia, D. K. Waiker, A. C. Nusbaum, H. Amawi, E. M. Kirwen, R. Christman, S. K. C. Arudra, L. Meijer, A. K. Tiwari and P. Trivedi, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 2663-2667.
35. D. Muñoz-Torrero, A. Mangoni, C. Guillou, S. Collina, J. Vanden Eynde, J. Rautio, G. Keserú, C. Hulme, K. Chibale, F. Luque, R. Karaman, M. Gütschow, H. Liu and R. Ragno, *Molecules*, 2017, **22**, 743.
36. N. Hussein, H. Amawi, C. Karthikeyan, F. S. Hall, R. Mittal, P. Trivedi, C. R. Ashby Jr and A. K. Tiwari, *Cancer Lett.*, 2017, **396**, 167-180.
37. J. Carmichael, W. G. DeGraff, A. F. Gazdar, J. D. Minna and J. B. Mitchell, *Cancer Res.*, 1987, **47**, 936-942.